A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme

Trial Profile

A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Alidornase alfa (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 07 Jun 2017 Results published in a Protalix Biosciences media release.
    • 07 Jun 2017 According to a Protalix Biotherapeutics media release, new clinical data from this trial will be presented at the 40th European Cystic Fibrosis Society Conference.
    • 23 May 2017 Status changed from active, no longer recruiting to completed. as reported in a Protalix Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top